News | April 07, 2025
Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
Bempedoic Acid administered as a 180-mg dose, is approved by the USFDA and European Union for the treatment of hypercholesterolemia
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
The product is expected to be available in a week’s time
Subscribe To Our Newsletter & Stay Updated
